MARKET

GNMK

GNMK

GenMark
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.42
+0.49
+3.28%
Closed 19:34 07/06 EDT
OPEN
15.09
PREV CLOSE
14.93
HIGH
15.52
LOW
14.85
VOLUME
1.67M
TURNOVER
--
52 WEEK HIGH
15.97
52 WEEK LOW
3.360
MARKET CAP
1.07B
P/E (TTM)
-21.2631
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GNMK stock price target is 15.25 with a high estimate of 17.00 and a low estimate of 14.00.

EPS

GNMK News

More
GenMark Diagnostics Announces its ePlex Respiratory Pathogen is Available for US Commercial Distribution
Benzinga · 06/29 11:04
GenMark Diagnostics Announces Commercial Launch of its ePlex® Respiratory Pathogen Panel 2 (RP2)
GenMark Diagnostics, Inc. (GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced that its ePlex® Respiratory Pathogen 2 (RP2) Panel is now available for U.S. commercial distribution and clinical use. The ePlex RP2 P
GlobeNewswire · 06/29 11:00
Hedge Funds Cashing Out Of GenMark Diagnostics, Inc (GNMK)
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. I
Insider Monkey · 06/28 20:07
Here’s a hedge fund strategy that just might work for you
marketwatch.com · 06/27 13:15
Will GenMark Diagnostics Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor of GenMark Diagnostics
Zacks · 06/19 16:16
GenMark Diagnostics (GNMK) Upgraded to Strong Buy: Here's What You Should Know
GenMark Diagnostics (GNMK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Zacks · 06/19 16:00
GenMark Diagnostics Chosen as Primary Provider of Rapid Diagnostic Testing for Vidant Health
GlobeNewswire · 06/16 13:00
GenMark Diagnostics Chosen As Primary Provider Of Rapid Diagnostic Testing For Vidant Health
Largest health system in eastern North Carolina turns to ePlex® platform for fast results on SARS-CoV-2, respiratory and blood stream infections CARLSBAD, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- GenMark
Benzinga · 06/16 12:15

Industry

Advanced Medical Equipment & Technology
+1.97%
Healthcare Equipment & Supplies
+1.39%

Hot Stocks

Symbol
Price
%Change

About GNMK

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.
More

Webull offers kinds of GenMark Diagnostics, Inc stock information, including NASDAQ:GNMK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNMK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNMK stock methods without spending real money on the virtual paper trading platform.